Showing 2731-2740 of 4063 results for "".
- Vision Expo Announces Topic for July 22 Virtual EYE2EYE Series Coffee Talkhttps://modernod.com/news/vision-expo-announces-topic-for-july-22-virtual-eye2eye-series-coffee-talk/2478039/On July 22 at 12:15 pm EDT, The Vision Council and Vision Expo will host “Open Your Eyes! What Allyship of Diversity & Inclusion Looks Like” as part of the Virtual EYE2EYE Series, a weekly series of virtual panels and interactive conversations inspired by Vision Expo’s EYE2EYE edu
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Women in Ophthalmology (WIO) 2020 Summer Symposium Goes Virtualhttps://modernod.com/news/women-in-ophthalmology-wio-2020-summer-symposium-goes-virtual/2477999/Due to the recent rise in COVID-19 cases in Florida, Women in Ophthalmology (WIO) has decided to is move its Summer Symposium to an all-virtual platform on August 21-23, 2020. “In classic WIO fashion, we have planned an innovative meeting like no other with 24 hours of CME, scientifi
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative
- ImprimisRx’s Patented Klarity-C 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometristshttps://modernod.com/news/imprimisrxs-patented-klarity-c-0-1-cyclosporine-preservative-free-formulation-may-now-be-prescribed-by-floridas-2000-optometrists/2477907/ImprimisRx announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. Klarity-C w
- Clearside Biomedical Announces Numerous Presentations at ARVO 2020https://modernod.com/news/clearside-biomedical-announces-numerous-presentations-at-arvo-2020/2477906/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector targeting the suprachoroidal space (SCS) are available online at the ARVO 2020 Meeting. Due to COVID-19, the ARVO 2020 Annual Meetin
- NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical for Ophthalmic Quinolone Antibiotichttps://modernod.com/news/ntc-grants-license-and-distribution-rights-in-israel-to-taro-pharmaceutical-for-ophthalmic-quinolone-antibiotic/2477905/NTC has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries. The product combines a quinolone antibiotic with an anti-inflammatory steroid
- Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Programhttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european-commission-for-adx-2191-retinal-disease-program/2477898/Aldeyra Therapeutics announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR),
- Tarsus Pharmaceuticals Announces Positive Results of Phase 2a Study for TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-phase-2a-study-for-tp-03-to-treat-demodex-blepharitis/2477893/Tarsus Pharmaceuticals announced positive results of its phase 2a Mars Study and the release later this month of the results of a phase 2b randomized controlled study. The Mars study demonstrated that the use of TP-03 for 4 weeks was well-tolerated and showed promising efficacy in the treatment o
- Study: Annual Costs for Diagnostic Tests Up to $25B, Antibody Tests Up to $19Bhttps://modernod.com/news/study-annual-costs-for-diagnostic-tests-up-to-25b-antibody-tests-up-to-19b/2479523/The estimated annual cost for diagnostic testing of COVID-19 will range from $6 billion to $25.1 billion, and the cost for antibody testing could vary from $5.2 billion to $19.1 billion, a new study found, according to a FierceHealthcare